title: Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.
abstract: OBJECTIVE
  To investigate the clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide (IVCY) in systemic sclerosis (SSc) patients with interstitial lung disease (ILD).
  
  
  METHODS
  Serum adiponectin levels were determined by a specific enzyme-linked immunosorbent assay in eight SSc patients with active ILD who underwent IVCY and 27 healthy controls. In patients, serum samples were drawn the day before each IVCY.
  
  
  RESULTS
  Serum adiponectin levels were significantly decreased in SSc patients with active ILD before the first IVCY compared with healthy controls [median (25-75 percentile): 3.21 (2.70-4.19) vs. 7.42 (6.06-10.82) μg/ml; P < 0.01). After the completion of whole IVCY, serum adiponectin levels were significantly increased [17.55 (6.47-39.45) μg/ml; P < 0.05] compared with the initial levels, and this increase significantly correlated with the decrease in ILD scores. Importantly, the dynamics of serum adiponectin levels during the IVCY therapy reflected its efficacy against SSc-ILD over the treatment and the follow-up period.
  
  
  CONCLUSIONS
  The monitoring of serum adiponectin levels during the IVCY treatment may be useful to identify SSc patients with ILD refractory to the treatment and at high risk for exacerbations during the follow-up period.
authors.affiliation: Department of Dermatology, University of Tokyo Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
authors.forename: Yuri
authors.initials: Y
authors.lastname: Masui
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Asano
authors.forename: Takehiro
authors.initials: T
authors.lastname: Takahashi
authors.forename: Sayaka
authors.initials: S
authors.lastname: Shibata
authors.forename: Kaname
authors.initials: K
authors.lastname: Akamata
authors.forename: Naohiko
authors.initials: N
authors.lastname: Aozasa
authors.forename: Shinji
authors.initials: S
authors.lastname: Noda
authors.forename: Takashi
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Yohei
authors.initials: Y
authors.lastname: Ichimura
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Toyama
authors.forename: Zenshiro
authors.initials: Z
authors.lastname: Tamaki
authors.forename: Hayakazu
authors.initials: H
authors.lastname: Sumida
authors.forename: Koichi
authors.initials: K
authors.lastname: Yanaba
authors.forename: Yayoi
authors.initials: Y
authors.lastname: Tada
authors.forename: Makoto
authors.initials: M
authors.lastname: Sugaya
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sato
authors.forename: Takafumi
authors.initials: T
authors.lastname: Kadono
mesh_terms: D052242:Adiponectin / Q000097:blood*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D017563:Lung Diseases, Interstitial / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D052242:Adiponectin; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide